PUBLISHER: Grand View Research | PRODUCT CODE: 2132274
PUBLISHER: Grand View Research | PRODUCT CODE: 2132274
The global biomarker discovery outsourcing services market size was valued at USD 17.0 billion in 2025 and is projected to grow from USD 19.9 billion in 2026 to USD 76.3 billion by 2033, at a CAGR of 21.1% from 2026 to 2033. North America dominated the market, accounting for the largest share of 43.8% in 2025. The industry is anticipated to grow owing to the increasing adoption of precision medicine, rising pharmaceutical and biotechnology research and development expenditure, growing outsourcing of biomarker discovery activities to specialized service providers, expanding application of biomarkers in oncology and other chronic diseases, and continuous advancements in genomics, proteomics, metabolomics, and multi-omics technologies.
The industry is anticipated to grow owing to the increasing adoption of precision medicine, rising pharmaceutical and biotechnology research and development expenditure, growing outsourcing of biomarker discovery activities to specialized service providers, expanding application of biomarkers in oncology and other chronic diseases, and continuous advancements in genomics, proteomics, metabolomics, and multi-omics technologies. The increasing complexity of biomarker identification and validation workflows, combined with the need for advanced analytical platforms and bioinformatics expertise, is encouraging drug developers to collaborate with specialized outsourcing partners that offer integrated discovery, validation, and data analysis capabilities across multiple therapeutic areas.
The increasing adoption of precision medicine remains a primary driver of market growth. Biomarkers play a critical role in patient stratification, target identification, treatment selection, and monitoring therapeutic response, making them an essential component of modern drug development. The growing number of targeted therapies and companion diagnostics entering clinical development is increasing the demand for advanced biomarker discovery services. The requirement for genomic sequencing, transcriptomics, proteomics, and bioinformatics analysis has further increased outsourcing among pharmaceutical and biotechnology companies seeking specialized scientific expertise and access to advanced laboratory technologies without expanding internal research infrastructure.
The growing outsourcing of biomarker discovery activities is another important factor supporting market expansion. Biomarker discovery requires access to sophisticated analytical instruments, high-quality biological samples, experienced scientific personnel, and advanced computational capabilities, which involve considerable investment and operational complexity. Therefore, pharmaceutical and biotechnology companies are increasingly partnering with contract research organizations and specialized biomarker service providers to improve development efficiency and accelerate clinical programs. This trend is further supported by continuous investments in advanced biomarker platforms. For instance, in July 2026, CellCarta launched its Global Digital Pathology and AI Consortium to integrate digital pathology, artificial intelligence, and spatial biology capabilities for biomarker discovery, patient stratification, and companion diagnostic development, further strengthening its outsourced biomarker discovery service offerings for precision medicine programs.
Market growth is moderated by the high cost of advanced omics technologies, challenges associated with biomarker validation and regulatory acceptance, and concerns related to biological sample quality and data standardization. The increasing adoption of artificial intelligence-driven biomarker discovery platforms, the expansion of multi-omics research, and the rising investment in precision oncology and personalized therapeutics are expected to create substantial opportunities for biomarker discovery outsourcing service providers over the coming years.
Thus, the biomarker discovery outsourcing services market is expected to witness steady growth as pharmaceutical and biotechnology companies continue to expand precision medicine research, increase outsourcing of specialized discovery activities, and invest in advanced biomarker-driven drug development programs. The continued evolution of multi-omics technologies, bioinformatics, and translational research capabilities is expected to further strengthen demand for integrated biomarker discovery outsourcing services.
Global Biomarker Discovery Outsourcing Services Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biomarker discovery outsourcing services market report based on biomarker type, therapeutic area, discovery phase, end-use, and region: